お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
966586

非癌領域の精密医療の世界市場 (2020-2030年):用途・エコシステム・地域別

Global Non-Oncology Precision Medicine Market: Focus on Application Area, Ecosystem Type, Country Data (15 Countries) - Analysis and Forecast, 2020-2030

出版日: | 発行: BIS Research Inc. | ページ情報: 英文 306 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
非癌領域の精密医療の世界市場 (2020-2030年):用途・エコシステム・地域別
出版日: 2020年10月15日
発行: BIS Research Inc.
ページ情報: 英文 306 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の非癌領域の精密医療の市場規模は予測期間中11.03%のCAGRで推移し、2019年の411億米ドルから、2030年には1299億6000万米ドルの規模に成長すると予測されています。分子レベル診断・治療に対する一般の意識の高まり、政府による各種イニシアチブの増加などの要因が同市場の成長を推進しています。また、分子診断の進歩、新たな個別化医療の開発に向けた企業による投資への関心の拡大、FDA承認薬の増加などの要因もさらなる成長を推進する見通しです。

当レポートでは、世界の非癌領域の精密医療の市場を調査し、市場の定義と概要、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制の枠組み、技術・特許の動向、市場規模の推移・予測、用途・エコシステム・地域/主要国など各種区分別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

エグゼクティブサマリー

第1章 製品の定義

第2章 調査範囲

第3章 調査手法

第4章 市場概要

  • イントロダクション
  • 予防に重点を置いた精密医療の実現技術
  • 精密医療の有望性・重要性

第5章 COVID-19の影響

第6章 産業分析

  • 法規制の枠組み・要件
  • 特許情勢

第7章 市場力学

  • 概要
  • 市場成長推進因子
  • 市場成長抑制因子
  • 市場機会

第8章 競合情勢

  • 主な戦略・展開
  • 市場シェア分析
  • 成長・シェア分析:企業別

第9章 市場分析・予測:用途別

  • 概要
  • 感染症
    • 呼吸器感染症
    • 胃腸感染症
    • 性感染症
    • その他
  • 神経/物理療法
    • 神経変性疾患
    • 神経精神障害
    • その他
  • 生活習慣病・内分泌系
  • 心臓血管
    • 心臓ミオパチー・不整脈
    • その他
  • 消化器病学
  • その他

第10章 市場分析・予測:エコシステム別

  • 概要
  • 応用科学
    • ゲノミクス
    • 薬理ゲノミクス
    • その他
  • 精密診断
    • 分子診断(MDx)
    • 医療画像処理
  • デジタルヘルス・IT
    • 臨床意思決定支援システム(CDSS)
    • ビッグデータアナリティクス
    • ITインフラ
    • ゲノミクスインフォマティクス
    • インシリコインフォマティクス
    • モバイルヘルス
  • 精密治療
    • 臨床試験
    • 細胞療法
    • 創薬・研究
    • 遺伝子治療

第11章 市場分析・予測:地域・主要国別

  • 概要
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • スペイン
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • オーストラリア
    • インド
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • その他の地域

第12章 企業プロファイル

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Almac Group Ltd.
  • Astra Zeneca
  • ASURAGEN INC.
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • bioMerieux S.A.
  • Bristol-Myers Squibb Company
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Invitae Corporation
  • Illumina, Inc.
  • Konica Minolta, Inc.
  • Laboratory Corporation of America Holdings
  • OPKO Health, Inc.
  • Partek, Inc.
  • Quest Diagnostics
  • QIAGEN N.V.*
  • Randox Laboratories Ltd.
  • Sanofi S.A.
  • Teva Pharmaceuticals Industries Ltd.
  • Thermo Fisher Scientific Inc.
図表

List of Tables

  • Table 4.1: Successful Non-Oncology Precision Medicine Interventions
  • Table 7.1: Percentage of Total Regional Aged Population (65 Years and Above: 2015 and 2030)
  • Table 9.1: FDA Approved Personalized Drugs Launched, Infectious Diseases, 2015-2019
  • Table 9.2: FDA Approved Personalized Drugs Launched, Neurology, 2015-2019
  • Table 9.3: FDA Approved Personalized Drugs Launched, Cardiology, 2015-2019
  • Table 9.4: FDA Approved Personalized Drugs Launched, Gastroenterology, 2015-2019
  • Table 9.5: FDA Approved Personalized Drugs Launched, Other Diseases, 2015-2019

List of Figures

  • Figure 1: Share of FDA Approved Non-Oncology Precision Medicine Drugs (2016-2018)
  • Figure 2: Global Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 3: Market Drivers, Opportunities, and Restraints
  • Figure 4: Share of Key Developments and Strategies, by Company (January 2016-August 2020)
  • Figure 5: Growth-Share Matrix for Global Non-Oncology Precision Medicine Market (by Company), 2019
  • Figure 6: Global Non-Oncology Precision Medicine Applications Market Share (Application Type), 2019-2030
  • Figure 7: Global Non-Oncology Precision Medicine Market (by Region)
  • Figure 2.1: Global Non-Oncology Precision Medicine Market Segmentation
  • Figure 3.1: Global Non-Oncology Precision Medicine Market Research Methodology
  • Figure 3.2: Primary Research Methodology
  • Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 3.4: Share of Total Number of Companies Profiled
  • Figure 4.1: Precision Medicine Model
  • Figure 4.2: Global Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 4.3: Enabling Technologies of Precision Medicine
  • Figure 4.4: Potential of Precision Medicine
  • Figure 5.1: Pre-COVID-19 and Post-COVID-19 Scenario of Global Non-Oncology Precision Medicine Market, 2017-2025
  • Figure 5.2: Supply Chain of Non-Oncology Precision Medicine
  • Figure 5.3: Key Factors of Supply Chain
  • Figure 5.4: Measures to Bridge the Supply-Chain Gap in Non-Oncology Precision Medicine Market
  • Figure 6.1: Share of Patents Assigned (2015-2019)
  • Figure 6.2: Total Number of Patents Assigned to Key Technologies, 2016-2018
  • Figure 7.1: Impact Analysis of Market Dynamics
  • Figure 7.2: Percentage of Patients With Experience of Ineffective Drug Treatment
  • Figure 7.3: Steady Increase in Usage of Personalized Medicine
  • Figure 8.1: Share of Key Developments and Strategies, January 2016-August 2020
  • Figure 8.2: Share of Product Offerings, January 2016-August 2020
  • Figure 8.3: Share of Partnerships and Alliances, January 2016-August 2020
  • Figure 8.4: Share of Funding and Investment, January 2016-August 2020
  • Figure 8.5: Share of Mergers and Acquisitions, January 2016-August 2020
  • Figure 8.6: Share of Funding and Investments, January 2016-August 2020
  • Figure 8.7: Market Share Analysis: Global Non-Oncology Precision Medicine Market, 2019
  • Figure 8.8: Growth-Share Matrix for Global Non-Oncology Precision Medicine Market (by Company), 2019
  • Figure 9.1: Global Non-Oncology Precision Medicine Applications Market Share (Application Type), 2019-2030
  • Figure 9.2: Global Non-Oncology Precision Medicine Infectious Diseases Market, 2019-2030
  • Figure 9.3: Global on-Oncology Precision Medicine Market (for Respiratory Infections), 2019-2030
  • Figure 9.4: Global on-Oncology Precision Medicine Market (for Gastrointestinal Infections), 2019-2030
  • Figure 9.5: Global on-Oncology Precision Medicine Market (by Sexually Transmitted Infections), 2019-2030
  • Figure 9.6: Global on-Oncology Precision Medicine Market (for Other Infections), 2019-2030
  • Figure 9.7: Global Non-Oncology Precision Medicine Neurology Market, 2019-2030
  • Figure 9.8: Global on-Oncology Precision Medicine Market (for Neurodegenerative Disorders), 2019-2030
  • Figure 9.9: Global on-Oncology Precision Medicine Market (for Neuropsychiatric Disorders), 2019-2030
  • Figure 9.10: Global Non-Oncology Precision Medicine Market (for Other Neurology Disorders), 2019-2030
  • Figure 9.11: Global Non-Oncology Precision Medicine Lifestyle and Endocrinology Market, 2019-2030
  • Figure 9.12: Global Non-Oncology Precision Medicine Cardiovascular Market, 2019-2030
  • Figure 9.13: Global on-Oncology Precision Medicine Market (for Cardiac Myopathies and Arrhythmia), 2019-2030
  • Figure 9.14: Global Oncology Precision Medicine Market (by Other Cardiovascular Disorder), 2019-2030
  • Figure 9.15: Global Non-Oncology Precision Medicine Gastroenterology Market, 2019-2030
  • Figure 9.16: Global Non-Oncology Precision Medicine Other Applications Market, 2019-2030
  • Figure 10.1: Global Non-Oncology Precision Medicine Market (by Applied Sciences), 2019-2030
  • Figure 10.2: Global Non-Oncology Precision Medicine Applied Sciences Market Share (by Type), 2019-2030
  • Figure 10.3: Global Non-Oncology Precision Medicine Genomics Market, 2019-2030
  • Figure 10.4: Global Non-Oncology Precision Medicine Genomics Market Share (by Technology)
  • Figure 10.5: Global Non-Oncology Precision Medicine PCR Market, 2019-2030
  • Figure 10.6: Global Non-Oncology Precision Medicine NGS Market, 2019-2030
  • Figure 10.7: Global Non-Oncology Precision Medicine Genome Editing Market, 2019-2030
  • Figure 10.8: Global Non-Oncology Precision Medicine Other Technologies Market, 2019-2030
  • Figure 10.9: Global Non-Oncology Precision Medicine Pharmacogenomics Market, 2019-2030
  • Figure 10.10: Global Non-Oncology Precision Medicine Other Applied Sciences Market, 2019-2030
  • Figure 10.11: Global Non-Oncology Precision Medicine Market (by Precision Diagnostics)
  • Figure 10.12: Global Non-Oncology Precision Medicine Market (by Precision Diagnostics), 2019-2030
  • Figure 10.13: Global Non-Oncology Precision Medicine Diagnostics Market Share (by Type), 2019-2030
  • Figure 10.14: Global Non-Oncology Precision Medicine Molecular Diagnostics Market, 2019-2030
  • Figure 10.15: Global Non-Oncology Precision Medicine Medical Imaging Market, 2019-2030
  • Figure 10.16: Global Non-Oncology Precision Medicine Digital Health and Information Technology Market,2019-2030
  • Figure 10.17: Global Non-Oncology Precision Medicine Digital Health and Information Technology Market Share (by Type), 2019-2030
  • Figure 10.18: Global Non-Oncology Precision Medicine CDSS Market, 2019-2030
  • Figure 10.19: Global Non-Oncology Precision Medicine Big Data Analytics Market, 2019-2030
  • Figure 10.20: Global Non-Oncology Precision Medicine IT Infrastructure Market, 2019-2030
  • Figure 10.21: Global Non-Oncology Precision Medicine Genomics Informatics Market, 2019-2030
  • Figure 10.22: Global Non-Oncology Precision Medicine In-Silico Informatics Market, 2019-2030
  • Figure 10.23: Global Non-Oncology Precision Medicine Mobile Health Market, 2019-2030
  • Figure 10.24: Global Non-Oncology Precision Medicine Therapeutics Market, 2019-2030
  • Figure 10.25: Global Non-Oncology Precision Medicine Therapeutics Market Share (by Type), 2019-2030
  • Figure 10.26: Global Non-Oncology Precision Medicine Clinical Trials Market, 2019-2030
  • Figure 10.27: Global Non-Oncology Precision Medicine Cell Therapy Market, 2019-2030
  • Figure 10.28: Global Non-Oncology Precision Medicine Drug Discovery and Research Market, 2019-2030
  • Figure 10.29: Global Non-Oncology Precision Medicine Gene Therapy Market, 2019-2030
  • Figure 11.1: Global Non-Oncology Precision Medicine Market (by Region)
  • Figure 11.2: North America Global Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.3: North America: Market Dynamics
  • Figure 11.4: North America Global Non-Oncology Precision Medicine Market (by Country), 2019-2030
  • Figure 11.5: U.S. Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.6: Canada Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.7: Europe Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.8: Europe: Market Dynamics
  • Figure 11.9: Europe Non-Oncology Precision Medicine Market (by Country), 2019-2030
  • Figure 11.10: Germany Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.11: France Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.12: Italy Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.13: The U.K. Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.14: Spain Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.15: Rest-of-Europe Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.16: Asia-Pacific Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.17: Asia-Pacific: Market Dynamics
  • Figure 11.18: Asia-Pacific Non-Oncology Precision Medicine Market (by Country), 2019-2030
  • Figure 11.19: China Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.20: Japan Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.21: Australia Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.22: India Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.23: Rest-of-Asia-Pacific Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.24: Latin America Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.25: Latin America: Market Dynamics
  • Figure 11.26: Latin America Global Non-Oncology Precision Medicine Market (by Country), 2019 and 2030
  • Figure 11.27: Brazil Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.28: Mexico Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.29: Mexico Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 11.30: Rest-of-the-World Non-Oncology Precision Medicine Market, 2019-2030
  • Figure 12.1: Abbott Laboratories.: Overall Product Offerings
  • Figure 12.2: Abbott Laboratories: Overall Financials, 2017-2019
  • Figure 12.3: Abbott Laboratories: Net Revenue (by Business Segment), 2017-2019
  • Figure 12.4: Abbott Laboratories: Net Revenue (by Region), 2017-2019
  • Figure 12.5: Abbott Laboratories: Research and Development Expense, 2017-2019
  • Figure 12.6: Abbott Laboratories: SWOT Analysis
  • Figure 12.7: Agilent Technologies, Inc.: Overall Product Offerings
  • Figure 12.8: Agilent Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 12.9: Agilent Technologies, Inc.: Net Revenue (by Business Segment), 2017-2019
  • Figure 12.10: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.11: Agilent Technologies, Inc.: Research and Development Expense, 2017-2019
  • Figure 12.12: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 12.13: Almac Group Ltd.: Overall Product Offerings
  • Figure 12.14: Almac Group Ltd.: SWOT Analysis
  • Figure 12.15: Astra Zeneca: Overall Product Portfolio
  • Figure 12.16: Astra Zeneca: Overall Financials, 2017-2019
  • Figure 12.17: Astra Zeneca: Revenue (by Business Segment), 2017-2019
  • Figure 12.18: Astra Zeneca: Revenue (by Region), 2017-2019
  • Figure 12.19: Astra Zeneca: SWOT Analysis
  • Figure 12.20: ASURAGEN, INC.: Overall Product Offerings
  • Figure 12.21: ASURAGEN INC.: SWOT Analysis
  • Figure 12.22: BGI Group.: Overall Product Portfolio
  • Figure 12.23: BGI Group: SWOT Analysis
  • Figure 12.24: Bio-Rad Laboratories, Inc: Overall Product Offerings
  • Figure 12.25: Bio-Rad Laboratories, Inc: Overall Financials, 2017-2019
  • Figure 12.26: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2017-2019
  • Figure 12.27: Bio-Rad Laboratories, Inc: Revenue (by Region), 2017-2019
  • Figure 12.28: Bio-Rad Laboratories, Inc. R&D Expenditure, 2017-2019
  • Figure 12.29: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 12.30: bioMerieux S.A.: Overall Product Portfolio
  • Figure 12.31: bioMerieux S.A.: Overall Financials, 2017-2019
  • Figure 12.32: bioMerieux S.A.: Revenue (by Segment), 2017-2019
  • Figure 12.33: bioMerieux S.A.: Revenue (by Region), 2018 and 2019
  • Figure 12.34: bioMerieux S.A.: SWOT Analysis
  • Figure 12.35: Bristol-Myers Squibb Company: Overall Product Portfolio
  • Figure 12.36: Bristol-Myers Squibb Company: Overall Financials, 2017-2019
  • Figure 12.37: Bristol-Myers Squibb Company R&D Expenditure, 2017-2019
  • Figure 12.38: Bristol-Myers Squibb Company: SWOT Analysis
  • Figure 12.39: Danaher Corporation: Overall Product Portfolio
  • Figure 12.40: Danaher Corporation: Overall Financials, 2017-2019
  • Figure 12.41: Danaher Corporation: Revenue (by Business Segment), 2017-2019
  • Figure 12.42: Danaher Corporation: SWOT Analysis
  • Figure 12.43: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 12.44: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 12.45: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
  • Figure 12.46: Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
  • Figure 12.47: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
  • Figure 12.48: F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Figure 12.49: Gilead Sciences, Inc.: Overall Product Portfolio
  • Figure 12.50: Gilead Sciences, Inc.: Overall Financials, 2017-2019
  • Figure 12.51: Gilead Sciences, Inc. : R&D Expenditure, 2017-2019
  • Figure 12.52: Gilead Science, Inc.: SWOT Analysis
  • Figure 12.53: GlaxoSmithKline Plc.: Overall Product Portfolio
  • Figure 12.54: GlaxoSmithKline plc: Overall Financials, 2017-2019
  • Figure 12.55: GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
  • Figure 12.56: GlaxoSmithKline plc: Revenue (by Region), 2017-2019
  • Figure 12.57: GlaxoSmithKline plc: R&D Expenditure, 2017-2019
  • Figure 12.58: GlaxoSmithKline plc: SWOT Analysis
  • Figure 12.59: Invitae Corporation: Overall Product Portfolio
  • Figure 12.60: Invitae Corporation: Overall Financials, 2017-2019
  • Figure 12.61: Invitae Corporation: Revenue (by Segment), 2017-2019
  • Figure 12.62: Invitae Corporation: Revenue (by Region), 2017-2019
  • Figure 12.63: Invitae Corporation: R&D Expenditure, 2017-2019
  • Figure 12.64: Invitae Corporation: SWOT Analysis
  • Figure 12.65: Illumina, Inc.: Overall Product Portfolio
  • Figure 12.66: Illumina, Inc.: Overall Financials, 2017-2019
  • Figure 12.67: Illumina, Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.68: Illumina, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.69: Illumina, Inc.: R&D Expenditure, 2017-2019
  • Figure 12.70: Illumina, Inc.: SWOT Analysis
  • Figure 12.71: Konica Minolta, Inc.: Overall Product Portfolio
  • Figure 12.72: Konica Minolta, Inc.: Overall Financials, 2017-2019
  • Figure 12.73: Konica Minolta, Inc.: Revenue (by Region), 2017-2019
  • Figure 12.74: Konica Minolta, Inc.: Research and Development Expense, 2017-2019
  • Figure 12.75: Konica Minolta, Inc.: SWOT Analysis
  • Figure 12.76: Laboratory Corporation of America Holdings.: Overall Product Portfolio
  • Figure 12.77: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
  • Figure 12.78: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
  • Figure 12.79: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
  • Figure 12.80: Laboratory Corporation of America Holdings: SWOT Analysis
  • Figure 12.81: OPKO Health, Inc.: Overall Product Portfolio
  • Figure 12.82: OPKO Health, Inc.: Overall Financials, 2017-2019
  • Figure 12.83: OPKO Health, Inc: Net Revenue (by Business Segment), 2017-2019
  • Figure 12.84: OPKO Health, Inc.: Net Revenue (by Region), 2017-2019
  • Figure 12.85: OPKO Health, Inc.: Research and Development Expense, 2017-2019
  • Figure 12.86: OPKO Health, Inc.: SWOT Analysis
  • Figure 12.87: Partek, Inc: Overall Product Portfolio
  • Figure 12.88: Partek, Inc.: SWOT Analysis
  • Figure 12.89: Quest Diagnostics Incorporated: Overall Product Offerings
  • Figure 12.90: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
  • Figure 12.91: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
  • Figure 12.92: Quest Diagnostics Incorporated: SWOT Analysis
  • Figure 12.93: QIAGEN N.V.: Overall Product Portfolio
  • Figure 12.94: QIAGEN N.V.: Overall Financials, 2017-2019
  • Figure 12.95: QIAGEN N.V.: Revenue (by Segment), 2017-2019
  • Figure 12.96: QIAGEN N.V.: Revenue (by Region), 2017-2019
  • Figure 12.97: QIAGEN N.V.: R&D Expenditure, 2017-2019
  • Figure 12.98: QIAGEN N.V.: SWOT Analysis
  • Figure 12.99: Randox Laboratories Ltd.: SWOT Analysis
  • Figure 12.100: Sanofi SA: Overall Product Portfolio
  • Figure 12.101: Sanofi SA: Overall Financials, 2017-2019
  • Figure 12.102: Sanofi SA: Revenue (by Segment), 2017-2019
  • Figure 12.103: Sanofi SA: Revenue (by Region), 2017-2019
  • Figure 12.104: Sanofi SA: R&D Expenditure, 2017-2019
  • Figure 12.105: Sanofi SA: SWOT Analysis
  • Figure 12.106: Teva Pharmaceuticals Industries Ltd.: Overall Product Portfolio
  • Figure 12.107: Teva Pharmaceuticals Industries Ltd.: Overall Financials, 2017-2019
  • Figure 12.108: Teva Pharmaceuticals Industries Ltd.: Revenue (by Region), 2017-2019
  • Figure 12.109: Teva Pharmaceuticals Industries Ltd. R&D Expenditure, 2017-2019
  • Figure 12.110: Teva Pharmaceuticals Industries Ltd.: SWOT Analysis
  • Figure 12.111: Thermo Fisher Scientific Inc.: Overall Product Portfolio
  • Figure 12.112: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
  • Figure 12.113: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
  • Figure 12.114: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
  • Figure 12.115: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
  • Figure 12.116: Thermo Fisher Scientific Inc.: SWOT Analysis
目次
Product Code: BHP0958SA

"Global Non-Oncology Precision Medicine Market to Reach $129.96 Billion by 2030."

Market Report Coverage - Non-Oncology Precision Medicine

Market Segmentation

  • By Application: Infectious Diseases, Neurology, Cardiovascular, Lifestyle and Endocrinology, Gastroenterology, Other Applications
  • By Ecosystem: Applied Sciences, Precision Diagnostics, Digital Health and Information Technology, Precision Therapeutics
  • By Region: North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World

Regional Segmentation

  • North America - U.S., Canada
  • Europe - Germany, France, Italy, U.K., Spain, Rest-of-Europe
  • Asia-Pacific - China, Japan, Australia, India, Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, Rest-of-LATAM
  • Rest-of-the-World

Growth Drivers

  • Improved availability of targeted therapies and decreasing trial and error-based prescription
  • Reduced chances of adverse drug reactions
  • Decreasing overall cost of genome sequencing
  • Rising prevalence of chronic diseases

Market Challenges

  • Unclear regulatory framework and reimbursement scenario for personalized medicine
  • Limited knowledge about molecular mechanism/interaction
  • Integrating and securing Electronic Health Record

Market Opportunities

  • Research alliance across industry and academia would accelerate the market entry
  • Strong product pipeline and increasing FDA approvals

Key Non-Oncology Precision Medicine Companies Profiled

Abbott Laboratories, Agilent Technologies, Inc., Asuragen, Inc., Almac Group, AstraZeneca PLC, Bristol Myers Squibb, bioMerieux SA., BGI, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, Danaher Corp., GlaxoSmithKline plc., Gilead Sciences, Inc. Illumina, Inc., Invitae Corporation, Opko Health, Inc., Laboratory Corporation of America Holdings, Pacific Biosciences of California, Inc., Partek Incorporated, Randox Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics

Key Questions Answered in this Report:

  • What are the various types of technologies available in the non-oncology precision medicine market, and what are the benefits offered by them?
  • What are the key development strategies implemented by the key players to stand out in this market?
  • What are the emerging technologies that can take over the current technologies for molecular diagnosis within the non-oncology precision medicine market?
  • How have the strategic collaborations among the key players and academia provided a push to product development within the non-oncology precision medicine market?
  • Which technology has witnessed maximum adoption in terms of patent filing and development of molecular therapeutics within the market, and why?
  • What are the regulations pertaining to the global non-oncology precision medicine market in different regions?
  • What are the initiatives implemented by different government bodies regulating the development and commercialization of non-oncology precision medicine products and associated platforms?
  • How has COVID-19 impacted the non-oncology precision medicine market?
  • How will the urgency of the pandemic influence the global non-oncology precision medicine market?
  • What are the leading companies dominating the global non-oncology precision medicine market?
  • What are the significant research and developmental investments performed by the key market players?
  • What is the reimbursement scenario of the products offered in the global non-oncology precision medicine market?
  • Based on the application area, which global non-oncology precision medicine market application area is anticipated to witness a massive rise in demand in the forecast period?
  • How is each segment of the global non-oncology precision medicine market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2030?

Market Overview

The precision medicine approach is used for several disease management, such as oncology, immunology, neurology, and infectious diseases. In the non-oncology precision medicine market, the application of molecular biology is for studying the cause of a patient's disease at the molecular level for diseases other than cancer, so that target-based therapies or individualized therapies can be applied to cure the patient's health-related problems.

The global non-oncology precision medicine market was valued at $41.1 in 2019, and it is expected to grow at an impressive double-digit rate of 11.03% and reach a value of $129.96 in 2030.

The existing non-oncology precision medicine market is favored by multiple factors, which include rising government initiatives, coupled up with the general population's growing awareness pertaining to molecular level diagnosis and treatment. Additionally, the increasing number of advancements in molecular diagnostics, more key players interested in investing for the development of novel personalized therapies, and increasing FDA approvals for such drugs among others.

Within the research report, the market is segmented on the basis of application (infectious diseases, neurology, cardiovascular, lifestyle and endocrinology, gastroenterology, other applications), ecosystem type (applied sciences, precision diagnostics, digital health and information technology, precision therapeutics), and region (North America, Europe, Asia Pacific, Latin America, and Rest-of-the-World). This segmentation highlights value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

The non-oncology precision medicine market witnessed 59 collaborations and partnerships, four fundings and investments, 44 product launches and enhancements,26 regulatory and legal activities,18 mergers and acquisitions, and six business expansions during the period January 2016-August 2020.

Major players within the non-oncology precision medicine market are Abbott Laboratories, Agilent Technologies, Inc., Asuragen, Inc., Almac Group, AstraZeneca PLC, Bristol Myers Squibb, bioMerieux SA., BGI, Bio-Rad Laboratories, Inc F. Hoffmann-La Roche AG, Danaher Corp., GlaxoSmithKline plc., Gilead Sciences, Inc. Illumina, Inc., Invitae Corporation, Opko Health, Inc., Laboratory Corporation of America Holdings, Pacific Biosciences of California, Inc., Partek Incorporated, Randox Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Thermofisher Scientific, QIAGEN, and Quest Diagnostics.

Table of Contents

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Scope of the Research Study

  • 2.1 Research Scope

3 Research Methodology

  • 3.1 Primary Data Sources
  • 3.2 Secondary Data Sources
  • 3.3 Market Estimation Model
  • 3.4 Selection Criteria for Company Profiles

4 Market Overview

  • 4.1 Introduction
  • 4.2 Enabling Technologies of Precision Medicine Emphasizing Focus on Prevention
  • 4.3 Promising Potential and Role of Precision Medicine

5 Impact of COVID-19 Pandemic on Global Non-Oncology Precision Medicine Market

  • 5.1 Unprecedented Demand for Non-Oncology Precision Medicine Due to COVID-19
  • 5.2 COVID-19 Affecting Supply Chain of Non-Oncology Precision Medicine-Based Therapies
  • 5.3 Measures Taken to Address Current Problem

6 Global Non-Oncology Precision Medicine Market: Industry Analysis

  • 6.1 Legal and Regulatory Framework and Requirements
    • 6.1.1 North America
      • 6.1.1.1 Regulatory Requirements in U.S.
    • 6.1.2 Europe
    • 6.1.3 Asia-Pacific
  • 6.2 Patent Landscape

7 Global Non-Oncology Precision Medicine Market: Market Dynamics

  • 7.1 Overview
  • 7.2 Market Driving Factors
    • 7.2.1 Improved Availability of Targeted Therapies and Decreasing Trial and Error-Based Prescription
    • 7.2.2 Reduced Chances of Adverse Drug Reactions
    • 7.2.3 Decreasing Overall Cost of Genome Sequencing
    • 7.2.4 Rising Prevalence of Chronic Diseases
  • 7.3 Market Restraining Factors
    • 7.3.1 Unclear Regulatory Framework and Reimbursement Scenario for Personalized Medicine
    • 7.3.2 Limited Knowledge About Molecular Mechanism/Interaction
    • 7.3.3 Integrating and Securing Electronic Health Records
  • 7.4 Market Opportunities
    • 7.4.1 Research Alliance Across Industry and Academia Accelerating Market Entry
    • 7.4.2 Strong Pipeline and Increasing FDA Approvals

8 Global Non-Oncology Precision Medicine Market: Competitive Landscape

  • 8.1 Key Strategies and Developments
    • 8.1.1 Product Offerings
    • 8.1.2 Partnerships and Alliances
    • 8.1.3 Regulatory and Legal
    • 8.1.4 Mergers and Acquisitions
    • 8.1.5 Funding and Investments
  • 8.2 Market Share Analysis
  • 8.3 Growth-Share Analysis (by Company), 2019

9 Global Non-Oncology Precision Medicine Market (by Application), $Billion, 2019-2030

  • 9.1 Overview
  • 9.2 Infectious Diseases
    • 9.2.1 Respiratory Infections
    • 9.2.2 Gastrointestinal Infections
    • 9.2.3 Sexually Transmitted Infections
    • 9.2.4 Others
  • 9.3 Neurology/Physiatry
    • 9.3.1 Neurodegenerative Disorders
    • 9.3.2 Neuropsychiatric Disorders
    • 9.3.3 Others
  • 9.4 Lifestyle and Endocrinology
  • 9.5 Cardiovascular
    • 9.5.1 Cardiac Myopathies and Arrhythmia
    • 9.5.2 Others
  • 9.6 Gastroenterology
  • 9.7 Other Applications

10 Global Non-Oncology Precision Medicine Market (by Ecosystem), $Billion, 2019-2030

  • 10.1 Overview
  • 10.2 Applied Sciences
    • 10.2.1 Genomics
    • 10.2.2 Global Non-Oncology Precision Medicine Genomics Market (by Technology)
      • 10.2.2.1 Polymerase Chain Reaction (PCR)
      • 10.2.2.2 Precision Medicine Next-Generation Sequencing (PM NGS)
      • 10.2.2.3 Genome Editing
      • 10.2.2.4 Other Technologies
    • 10.2.3 Pharmacogenomics
    • 10.2.4 Other Applied Sciences
  • 10.3 Precision Diagnostics
    • 10.3.1 Molecular Diagnostics (MDx)
    • 10.3.2 Medical Imaging
  • 10.4 Digital Health and Information Technology
    • 10.4.1 Clinical Decision Support Systems (CDSS)
    • 10.4.2 Big Data Analytics
    • 10.4.3 IT Infrastructure
    • 10.4.4 Genomics Informatics
    • 10.4.5 In-Silico Informatics
    • 10.4.6 Mobile Health
  • 10.5 Precision Therapeutics
    • 10.5.1 Clinical Trials
    • 10.5.2 Cell Therapy
    • 10.5.3 Drug Discovery and Research
    • 10.5.4 Gene Therapy

11 Global Non-Oncology Precision Medicine Market (by Region), $Billion, 2019-2030

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 France
    • 11.3.3 Italy
    • 11.3.4 U.K.
    • 11.3.5 Spain
    • 11.3.6 Rest-of-Europe
  • 11.4 Asia-Pacific (APAC)
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 Australia
    • 11.4.4 India
    • 11.4.5 Rest-of-Asia-Pacific
  • 11.5 Latin America
    • 11.5.1 Brazil
    • 11.5.2 Mexico
    • 11.5.3 Rest-of-LATAM
  • 11.6 Rest-of-the-World
    • 11.6.1 Rest-of-the-World Non-Oncology Precision Medicine Market Dynamics

12 Company Profiles

  • 12.1 Abbott Laboratories
    • 12.1.1 Company Overview
    • 12.1.2 Role of Abbott Laboratories in Global Non-Oncology Precision Medicine Market
    • 12.1.3 Financials
    • 12.1.4 SWOT Analysis
  • 12.2 Agilent Technologies, Inc.
    • 12.2.1 Company Overview
    • 12.2.2 Role of Agilent Technologies, Inc. in Global Non-Oncology Precision Medicine Market
    • 12.2.3 Financials
    • 12.2.4 SWOT Analysis
  • 12.3 Almac Group Ltd.
    • 12.3.1 Company Overview
    • 12.3.2 Role of Almac Group Ltd. in Global Non-Oncology Precision Medicine Market
    • 12.3.3 SWOT Analysis
  • 12.4 Astra Zeneca
    • 12.4.1 Company Overview
    • 12.4.2 Role of Astra Zeneca in Global Non-Oncology Precision Medicine Market
    • 12.4.3 Financials
    • 12.4.4 SWOT Analysis
  • 12.5 ASURAGEN INC.
    • 12.5.1 Company Overview
    • 12.5.2 Role of ASURAGEN Inc. in Global Non-Oncology Precision Medicine Market
    • 12.5.3 SWOT Analysis
  • 12.6 BGI Group
    • 12.6.1 Company Overview
    • 12.6.2 Role of BGI Group in Global Non-Oncology Precision Medicine Market
    • 12.6.3 SWOT Analysis
  • 12.7 Bio-Rad Laboratories, Inc.
    • 12.7.1 Company Overview
    • 12.7.2 Role of Bio-Rad Laboratories, Inc.in Global Non-Oncology Precision Medicine Market
    • 12.7.3 Financials
    • 12.7.4 SWOT Analysis
  • 12.8 bioMerieux S.A.
    • 12.8.1 Company Overview
    • 12.8.2 Role of bioMerieux SA. in Global Non-Oncology Precision Medicine Market
    • 12.8.3 Financials
    • 12.8.4 SWOT Analysis
  • 12.9 Bristol-Myers Squibb Company
    • 12.9.1 Company Overview
    • 12.9.2 Role of Bristol-Myers Squibb Company in Global Non-Oncology Precision Medicine Market
    • 12.9.3 Financials
    • 12.9.4 SWOT Analysis
  • 12.1 Danaher Corporation
    • 12.10.1 Company Overview
    • 12.10.2 Role of Danaher Corporation in Global Non-Oncology Precision Medicine Market
    • 12.10.3 Financials
    • 12.10.4 SWOT Analysis
  • 12.11 F. Hoffmann-La Roche Ltd
    • 12.11.1 Company Overview
    • 12.11.2 Role of F. Hoffman-LA Roche Ltd in Global Non-Oncology Precision Medicine Market
    • 12.11.3 Financials
    • 12.11.4 SWOT Analysis
  • 12.12 Gilead Sciences, Inc.
    • 12.12.1 Company Overview
    • 12.12.2 Role of Gilead Sciences, Inc. in Global Non-Oncology Precision Medicine Market
    • 12.12.3 Financials
    • 12.12.4 SWOT Analysis
  • 12.13 GlaxoSmithKline plc
    • 12.13.1 Company Overview
    • 12.13.2 Role of GlaxoSmithKline Plc in Global Non-Oncology Precision Medicine Market
    • 12.13.3 Financials
    • 12.13.4 SWOT Analysis
  • 12.14 Invitae Corporation
    • 12.14.1 Company Overview
    • 12.14.2 Role of Invitae Corporation in Global Non-Oncology Precision Medicine Market
    • 12.14.3 Financials
    • 12.14.4 SWOT Analysis
  • 12.15 Illumina, Inc.
    • 12.15.1 Company Overview
    • 12.15.2 Role of Illumina, Inc. in Global Non-Oncology Precision Medicine Market
    • 12.15.3 Financials
    • 12.15.4 SWOT Analysis
  • 12.16 Konica Minolta, Inc.
    • 12.16.1 Company Overview
    • 12.16.2 Role of Konica Minolta, Inc. in Global Non-Oncology Precision Medicine Market
    • 12.16.3 Financials
    • 12.16.4 SWOT Analysis
  • 12.17 Laboratory Corporation of America Holdings
    • 12.17.1 Company Overview
    • 12.17.2 Role of Laboratory Corporation of America Holdings in Global Non-Oncology Precision Medicine Market
    • 12.17.3 Financials
    • 12.17.4 SWOT Analysis
  • 12.18 OPKO Health, Inc.
    • 12.18.1 Company Overview
    • 12.18.2 Role of OPKO Health, Inc. in Global Non-Oncology Precision Medicine Market
    • 12.18.3 Financials
    • 12.18.4 SWOT Analysis
  • 12.19 Partek, Inc.
    • 12.19.1 Company Overview
    • 12.19.2 Role Partek, Inc. in Global Non-Oncology Precision Medicine Market
    • 12.19.3 SWOT Analysis
  • 12.2 Quest Diagnostics
    • 12.20.1 Company Overview
    • 12.20.2 Role of Quest Diagnostics in Global Non-Oncology Precision Medicine Market
    • 12.20.3 Financials
    • 12.20.4 SWOT Analysis
  • 12.21 QIAGEN N.V.*
    • 12.21.1 Company Overview
    • 12.21.2 Role of QIAGEN N.V. in Global Non-Oncology Precision Medicine Market
    • 12.21.3 Financials
    • 12.21.4 SWOT Analysis
  • 12.22 Randox Laboratories Ltd.
    • 12.22.1 Company Overview
    • 12.22.2 Role of Randox Laboratories Ltd. in Global Non-Oncology Precision Medicine Market
    • 12.22.3 SWOT Analysis
  • 12.23 Sanofi S.A.
    • 12.23.1 Company Overview
    • 12.23.2 Role of Sanofi SA in Global Non-Oncology Precision Medicine Market
    • 12.23.3 Financials
    • 12.23.4 SWOT Analysis
  • 12.24 Teva Pharmaceuticals Industries Ltd.
    • 12.24.1 Company Overview
    • 12.24.2 Role of Teva Pharmaceuticals Industries Ltd. in Global Non-Oncology Precision Medicine Market
    • 12.24.3 Financials
    • 12.24.4 SWOT Analysis
  • 12.25 Thermo Fisher Scientific Inc.
    • 12.25.1 Company Overview
    • 12.25.2 Role of Thermo Fisher Scientific Inc. in Global Non-Oncology Precision Medicine Market
    • 12.25.3 Financials
    • 12.25.4 SWOT Analysis
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.